Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery
Recruitment status was: Active, not recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced salivary gland cancer that cannot be removed during surgery.
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Gemcitabine for Advanced Salivary Cancer: A Phase II Study|
|Study Start Date:||January 1999|
- Evaluate the response rate of patients with incurable salivary gland cancer treated with gemcitabine.
- Evaluate the time to progression and toxicity of this therapy in these patients.
OUTLINE: This is a multicenter study.
Patients receive gemcitabine IV for 30 minutes on days 1, 8, and 15 of each 28 day course. Patients receive a minimum of 2 courses of treatment. Patients may continue treatment in the absence of disease progression or unacceptable toxicity.
Patients are followed every 2 months.
PROJECTED ACCRUAL: This study will accrue a total of 16-60 patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003744
|United States, Illinois|
|University of Chicago Cancer Research Center|
|Chicago, Illinois, United States, 60637-1470|
|United States, Massachusetts|
|Massachusetts General Hospital Cancer Center|
|Boston, Massachusetts, United States, 02114|
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Marshall R. Posner, MD||Dana-Farber Cancer Institute|